Clinical Trial Update: Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating daptomycin safety and efficacy for complicated skin and skin structure infections and bacteremia in patients with renal impairment was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aureus Bacteremia
• Complicated Skin and Skin Structure Infections
• Renal Impairment

Drugs mentioned

• Daptomycin (daptomycin)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia | Phase 4 | Status: TERMINATED | Results posted: 2015-05-13